11.18

4.79% -0.53

Neumora Therapeutics Inc (NMRA)

Overview News Price History Option Chain Financials Why NMRA Down? Discussions Forecast

Neumora Therapeutics Inc stock is traded at $11.18, with a volume of 866.76K. It is down -4.79% in the last 24 hours and down -24.47% over the past month. Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has rapidly scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. The company expects to continue to progress in the development of its pipeline with the planned initiation of multiple clinical trials across its programs over the next 12 to 18 months, which supports numerous anticipated data readouts.

Previous Close:

$11.71

Open:

$11.02

24h Volume:

866.76K

Relative Volume:

0.99

Market Cap:

$1.77B

Revenue:

Net Income/Loss:

$-274.18M

P/E Ratio:

-6.5068

EPS:

-1.7182

Net Cash Flow:

$-198.33M

1W Performance:

-4.95%

1M Performance:

-24.47%

6M Performance:

+20.53%

1Y Performance:

-5.92%

1-Day Range:

$10.66

$11.27

1-Week Range:

$10.66

$12.27

52-Week Range:

$8.33

$21.00

Neumora Therapeutics Inc Stock (NMRA) Company Profile

Name

Neumora Therapeutics Inc

Sector

Healthcare (1181)

Industry

Biotechnology (680)

Phone

(857) 760-0900

Address

490 ARSENAL WAY, SUITE 200, WATERTOWN

Employee

108

Twitter

Next Earnings Date

Latest SEC Filings

NMRA's Discussions on Twitter

Neumora Therapeutics Inc Stock (NMRA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-12-23	Initiated	Deutsche Bank	Hold
Oct-10-23	Initiated	BofA Securities	Buy
Oct-10-23	Initiated	Guggenheim	Buy
Oct-10-23	Initiated	JP Morgan	Overweight
Oct-10-23	Initiated	RBC Capital Mkts	Outperform
Oct-10-23	Initiated	Stifel	Buy
Oct-10-23	Initiated	William Blair	Outperform

View All

Neumora Therapeutics Inc Stock (NMRA) Latest News

01:05 AM

Neumora Therapeutics (NMRA) to Release Earnings on Tuesday - MarketBeat

01:05 AM

08:39 AM

Auour Investments LLC Purchases New Holdings in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - MarketBeat

08:39 AM

07:30 AM

This Cognex Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Benzinga

07:30 AM

07:12 AM

Neumora Therapeutics (NASDAQ:NMRA) Downgraded to "Neutral" Rating by JPMorgan Chase & Co. - MarketBeat

07:12 AM

Oct 31, 2024

Critical Analysis: Neumora Therapeutics (NMRA) and The Competition - Defense World

Oct 31, 2024

Oct 29, 2024

Neumora Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024 - The Manila Times

Oct 29, 2024

Oct 27, 2024

(NMRA) On The My Stocks Page - Stock Traders Daily

Oct 27, 2024

Oct 25, 2024

Neumora Therapeutics (NASDAQ:NMRA) Trading Down 4.5%Time to Sell? - MarketBeat

Oct 25, 2024

Oct 23, 2024

Neumora Therapeutics (NASDAQ:NMRA) Sees Large Volume IncreaseTime to Buy? - MarketBeat

Oct 23, 2024

Oct 22, 2024

Neumora Therapeutics (NASDAQ:NMRA) Shares Gap Down Following Insider Selling - Defense World

Oct 22, 2024

Oct 21, 2024

SG Americas Securities LLC Lowers Holdings in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World

Oct 21, 2024

Bleakley Financial Group LLC Sells 1,966 Shares of Vanguard Mid-Cap Growth ETF (NYSEARCA:VOT) - Defense World

Oct 21, 2024

Neumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Sold by SG Americas Securities LLC - MarketBeat

Oct 21, 2024

Oct 19, 2024

Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat

Oct 19, 2024

Oct 18, 2024

Neumora Therapeutics, Inc. (NASDAQ:NMRA) Director Sells $239,254.47 in Stock - MarketBeat

Oct 18, 2024

Neumora Therapeutics director Matthew Fust sells $370,961 in stock - Investing.com India

Oct 18, 2024

Neumora Therapeutics director Matthew Fust sells $370,961 in stock By Investing.com - Investing.com South Africa

Oct 18, 2024

Neumora Therapeutics (NASDAQ:NMRA) Rating Reiterated by Needham & Company LLC - MarketBeat

Oct 18, 2024

Oct 17, 2024

(NMRA) Investment Analysis - Stock Traders Daily

Oct 17, 2024

Oct 16, 2024

This trade activity should not be overlooked: Neumora Therapeutics Inc. (NMRA) - SETE News

Oct 16, 2024

Neumora Therapeutics: A Story Of A Class II Biotech (NASDAQ:NMRA) - Seeking Alpha

Oct 16, 2024

Oct 15, 2024

Neumora Therapeutics (NASDAQ:NMRA) Shares Gap Down After Insider Selling - Defense World

Oct 15, 2024

Oct 14, 2024

Have you been able to find a good deal on Neumora Therapeutics Inc.’s shares? - US Post News

Oct 14, 2024

Oct 13, 2024

Neumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Acquired by The Manufacturers Life Insurance Company - MarketBeat

Oct 13, 2024

Oct 12, 2024

Acrivon Therapeutics Launches Phase 1 Cancer Trial, Advances Oncology Pipeline - Yahoo Finance

Oct 12, 2024

Oct 11, 2024

Neumora Therapeutics executive sells over $200k in company stock By Investing.com - Investing.com Australia

Oct 11, 2024

Neumora Therapeutics executive sells over $200k in company stock - Investing.com India

Oct 11, 2024

Neumora Therapeutics, Inc. (NASDAQ:NMRA) Insider Robert A. Lenz Sells 5,563 Shares - MarketBeat

Oct 11, 2024